OBJECTIVES: Poorer diabetes care and outcomes that are common in racial and ethnic minority populations, may partially be attributed to more barriers to medications among minority populations than whites. This study aimed to examine racial differences in the use of newer class pharmacological treatments in the US, using a nationally representative sample of non-institutionalized population. METHODS: This cross-sectional study analyzed the 2014 Household Component and Prescribed Medicines files of the Medical Expenditure Panel Survey (MEPS). Use of newer class pharmacological treatment was defined as any record of prescription fill for type 2 sodium-glucose co-transporter (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitor and glucagon-like peptide-1 (GLP-1) in 2014. The use rate was reported and compared between non-Hispanic whites and minorities. Estimates were weighted to the total American non-institutionalized population (WTP). Logistic regression models were employed to assess the association of racial groups and use of any newer anti-diabetics. RESULTS: